Open access
Aug 2026
Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer.
The discovery of dual RET/AurB inhibitors with potent activity in NSCLC cells is reported, establishing a dual-targeted RET/AurB inhibition strategy that addresses complementary oncogenic vulnerabilities in NSCLC and provides a strong foundation for continued optimization and development.
Maha Hanafi, Baha’a Jabali, Daniel Armstrong et al.
· Bioorganic chemistry (Print) · 0 citations